We have demonstrated that the incorporation of radiomic features along with conventional clinical factors was superior to the performance of clinical-factors alone model in prediction of PFS in EGFR-mutant adenocarcinoma patients treated with first-line EGFR TKIs. This evidence concerns the gene EGFR and adenocarcinoma.